Dramatic response to temozolomide, irinotecan, and bevacizumab for recurrent medulloblastoma with widespread osseous metastases

Phillip A. Bonney, Joshua A. Santucci, Adrian J. Maurer, Michael E. Sughrue, Rene Y. McNall-Knapp, James D. Battiste

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

There is little evidence to guide the choice of chemotherapeutic agents for osseous metastases in medulloblastoma. Recently, triple therapy with temozolomide, irinotecan, and bevacizumab has been reported to have efficacy in recurrent medulloblastoma, and this regimen alone and in combination with other agents has been tested in several early-phase clinical trials. Here we report a 20-year-old woman with multiply-relapsed medulloblastoma with numerous osseous metastases 8 years after original diagnosis who responded dramatically to temozolomide, irinotecan, and bevacizumab therapy. This case highlights the potential for this regimen in treating osseous metastases in medulloblastoma.

Original languageEnglish (US)
Pages (from-to)161-163
Number of pages3
JournalJournal of Clinical Neuroscience
Volume26
DOIs
StatePublished - Apr 1 2016

Keywords

  • Bevacizumab
  • Irinotecan
  • Medulloblastoma
  • Osseous metastasis
  • Recurrent
  • Temozolomide

ASJC Scopus subject areas

  • Surgery
  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Fingerprint

Dive into the research topics of 'Dramatic response to temozolomide, irinotecan, and bevacizumab for recurrent medulloblastoma with widespread osseous metastases'. Together they form a unique fingerprint.

Cite this